Monopar Therapeutics Inc (MNPR)

$15.73

-0.05

(-0.32%)

Market is closed - opens 8 PM, 08 Nov 2024

Performance

  • $15.31
    $16.05
    $15.73
    downward going graph

    2.67%

    Downside

    Day's Volatility :4.62%

    Upside

    2.0%

    downward going graph
  • $1.37
    $38.50
    $15.73
    downward going graph

    91.29%

    Downside

    52 Weeks Volatility :96.44%

    Upside

    59.14%

    downward going graph

Returns

PeriodMonopar Therapeutics IncIndex (Russel 2000)
3 Months
443.95%
0.0%
6 Months
314.17%
0.0%
1 Year
709.23%
0.0%
3 Years
-37.63%
-27.4%

Highlights

Market Capitalization
68.2M
Book Value
$1.73
Earnings Per Share (EPS)
-2.1
Wall Street Target Price
18.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-53.45%
Return On Equity TTM
-102.31%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
Diluted Eps TTM
-2.1
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.95
EPS Estimate Next Year
-2.48
EPS Estimate Current Quarter
-0.09
EPS Estimate Next Quarter
-0.1

Analyst Recommendation

Buy
    87%Buy
    12%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for Monopar Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
6
7
Hold
1
2
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 14.43%

Current $15.73
Target $18.00

Technicals Summary

Sell

Neutral

Buy

Monopar Therapeutics Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Monopar Therapeutics Inc
Monopar Therapeutics Inc
210.63%
314.17%
709.23%
-37.63%
-88.09%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-18.01%
-15.81%
-1.7%
31.13%
150.21%
Biontech Se
Biontech Se
-12.27%
17.34%
4.17%
-56.04%
478.94%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
2.34%
76.9%
60.41%
45.24%
198.24%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
10.04%
20.33%
30.51%
156.8%
152.08%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Monopar Therapeutics Inc
Monopar Therapeutics Inc
NA
NA
NA
-1.95
-1.02
-0.53
NA
1.73
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
20.49
20.54
1.22
44.74
0.17
0.07
NA
272.04
Biontech Se
Biontech Se
160.8
NA
0.04
-2.99
-0.03
-0.02
NA
85.17
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-1.87
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
1.27
0.19
-0.03
0.12
NA
60.66
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Monopar Therapeutics Inc
Monopar Therapeutics Inc
Buy
$59.7M
-88.09%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$91.1B
150.21%
20.49
33.61%
Biontech Se
Biontech Se
Buy
$26.5B
478.94%
160.8
-18.75%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$34.8B
198.24%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$121.6B
152.08%
32.84
-4.51%

Insights on Monopar Therapeutics Inc

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 45.8% return, outperforming this stock by 83.6%

Institutional Holdings

    Company Information

    monopar therapeutics inc., a biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the united states. it is involved in developing validive, a clonidine mucobuccal tablet that is in phase iii for the treatment of radiation induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin, a topoisomerase ii-alpha targeted analog of doxorubicin engineered to retain anticancer activity and for minimizing toxic effects on the heart; and mnpr-101, a humanized monoclonal antibody for treating advanced solid cancers. the company has a collaboration grupo espaã±ol de investigaciã³n en sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; and northstar medical radioisotopes, llc to develop radio-immuno-therapeutics targeting severe covid-19. monopar therapeutics inc. was founded in 2014 and is headquartered in wilmette, illinois.

    Organization
    Monopar Therapeutics Inc
    Employees
    9
    CEO
    Dr. Christopher M. Starr Ph.D.
    Industry
    Health Technology

    FAQs